bioAffinity Technologies, Inc. (BIAF)vsNatera Inc (NTRA)
BIAF
bioAffinity Technologies, Inc.
$7.95
-15.34%
HEALTHCARE · Cap: $4.78M
NTRA
Natera Inc
$328.93
+0.86%
HEALTHCARE · Cap: $46.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 45775% more annual revenue ($2.71B vs $5.90M). NTRA leads profitability with a -7.1% profit margin vs -257.3%. BIAF earns a higher WallStSmart Score of 34/100 (F).
BIAF
Avoid34
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
19.0% revenue growth
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -433.7% — below average capital efficiency
0.0% earnings growth
Weak financial health signals
Trading at 25.9x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BIAF
The strongest argument for BIAF centers on Price/Book, Revenue Growth. Revenue growth of 19.0% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : BIAF
The primary concerns for BIAF are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
BIAF profiles as a growth stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.53 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
BIAF generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
BIAF scores higher overall (34/100 vs 31/100) and 19.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
bioAffinity Technologies, Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?